Biopharma Gets Green Light for Hypertension Study

Source: Streetwise Reports   09/13/2017 Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm’s near-term clinical trial and catalysts. A Sept. 11 research report revealed Quantum Genomics SA’s (ALQGC:PA; . . . → Read More: Biopharma Gets Green Light for Hypertension Study Similar Articles: Maxim Raises Target Price of Biotech Company HIV Vaccine Clinical Study Results in High Immune Response Rates in Healthy Subjects Mesoblast Heart Failure Trial Delivers Positive Interim Results